Financings Of The Fortnight Finds Reasons For Biopharma Hope In Recent Venture Capital News
This article was originally published in The Pink Sheet Daily
Executive Summary
Plus details on recent financings by Cleave Biosciences, Incline Therapeutics, DNAnexus and Zeltiq Aesthetics.
You may also be interested in...
START-UP's 2011 Life Science Venture Capital Survey: Device Investors Feel The Sting Of FDA, Economy And Reform
START-UP's first life science venture survey asked all VCs how they feel about the state of the industry. Medical device VCs' answers reveal feelings of being beaten down by the FDA and the recession, and general concerns about the sector's ability to generate returns. Includes sidebar, "VCs Survive Amid Few Exits And Many Goodbyes."
START-UP's 2011 Life Science Venture Capital Survey: Biopharmaceutical Investors Let Some Sunshine In
In START-UP's first life science venture survey, biopharma investors have plenty to complain about -- and they do -- but their generally positive outlook stands in contrast to that of their peers focused on medtech. Includes sidebar, "VCs Survive Amid Few Exits And Many Goodbyes."
The A-List: 2010's Trend-Shaping Series A Financings
Investments for start-ups seeking their first infusion of venture capital continues to be scarce as venture firms seek later-stage opportunities and liquidity to improve their own chances of raising new funds.